57
Participants
Start Date
August 31, 2009
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Palonosetron (PALO)
Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
The Preston Robert Tisch Brain Tumor Center at Duke, Durham
Lead Sponsor
Eisai Inc.
INDUSTRY
Duke University
OTHER